Common Mistakes in Philippine Food CPR Registration: Applicant, Licence Class, Labels, Ingredients and Testing

Mistake one: the wrong applicant, the expensive one because it cannot be patched

Bottom line: this is the costliest of the five, because no supplementary document repairs it. Once the applicant is wrong, you are effectively starting again, and every document already issued in that entity's name has to be redone.

What it looks like. Three variants. A foreign factory or brand owner assumes it can apply directly, and discovers halfway through document collection that the applicant must be a licensed local entity. Or a local trading company is enlisted to lend its name without anyone checking what its licence covers or agreeing who owns the certificate. Or a group picks the wrong affiliate to file — one with no relevant business activity, chosen simply because it already holds a licence.

Why it happens. Because in other markets the registrant and the brand owner are often the same party. Here, the registration sits under a locally licensed entity, and that determines whose name is on the certificate and who can act on it afterwards. A foreign party either establishes its own licensed entity or files through a licensed representative.

What it costs. Importer particulars on the label are rebuilt, the letter of authorisation is reissued, foreign documents may have to be reapplied for and re-legalised under a different addressee, and any pending application is withdrawn or abandoned. The quieter cost is commercial: a certificate registered to a distributor does not travel with you when you change channel partners. The link between channel structure and certificate ownership is covered in structuring distribution in the Philippines.

How to catch it before filing. Write down answers to three questions: whose name will the certificate be in? If we change partners in two years, what happens to it? Does this entity's licence actually cover the activity we will be doing? If any answer is missing, stop collecting documents. When the applicant must be settled is covered in sequence and dependencies. Yixing's product access practice resolves these three in the first meeting, because they decide whose name goes on everything downstream.

Mistake two: a licence class that does not match the business

Bottom line: an FDA License to Operate is issued against declared activities, not as a general permit. Holding one does not mean it covers what you are actually doing.

What it looks like. Most typically, using a distribution-class licence to do what an importer does. Then there is contract manufacturing locally while filing own-brand products on a trading-class licence. Then a group where one company holds the licence while another actually buys and receives the goods, so the filing entity and the operating entity are different. And finally premises mismatches: the address on the licence differs from where storage and operations actually happen, when the licence is tied to inspectable premises.

Why it happens. Because in everyday conversation the licence is treated as a single generic thing, and few people ask which activities it lists. The problem also surfaces late — nobody asks about your future plans when the licence is issued, but an evaluator does check activity coverage when you file products.

What it costs. There is no cure inside the product application. Once eligibility is questioned, the product side stops until the licensing side is corrected, and amending or adding activities to a licence takes its own time, pushing the entire timeline back a full stage. If goods are already in transit when this surfaces, the cost becomes immediate and concrete.

How to catch it before filing. Take the licence out and check three things word for word: do the listed activities cover this filing; do the company name and address match the corporate registration and your actual operating address exactly; and does the validity period cover the entire projected review period? That last one is the most overlooked — a licence expiring mid-review affects the products beneath it, as explained in FDA LTO renewal and the consequences of a lapse. What the licence itself covers and how it is obtained is in permits required to import food into the Philippines.

Mistake three: non-compliant labels, and the only three ways they go wrong

Bottom line: labels are the most frequent source of failure, but from a filing standpoint there are only three failure modes: something is missing, the label disagrees with the dossier, or a claim crosses a line. This article covers how those three present at filing; how to write each particular is not repeated here.

Mode one: missing particulars and wrong format. The Philippines prescribes a full set of mandatory particulars and forms of expression for prepackaged food labels — required items, language, units, date marking, allergen presentation. The common exporter approach is to translate the home-market pack directly, which produces a label that is complete by one standard and deficient by another. The complete rules are in mandatory particulars for prepackaged food labels, with cross-category baselines in Philippine product labeling requirements, and are not repeated here.

Mode two: the label disagrees with the dossier. This is the one you are most likely to miss yourself, because the label looks compliant in isolation — the problem is that it does not tie out with the formulation declaration, the specification sheet and the test report. A product name appears as a literal translation in one document and as an English trade name in another; net content is nominal in one place and measured in another; ingredient ordering differs from the declared formulation. Evaluators review labels by three-way comparison, and any mismatch is cited.

Mode three: claims that cross a line. This covers prohibited or misleading representations, such as emphasising the absence of something the product never contained, and wording that reaches into physiological effect. The second kind is not merely an artwork fix: once a claim points at an effect, the product may be pushed toward a stricter pathway — see supplement registration and where the claim boundary sits.

How to catch it before filing. Run two passes in this order. First audit the label against the labeling rules item by item. Then run a three-way comparison against the dossier on product name, specification, net content, ingredient list, shelf life, manufacturer and importer particulars, and country of origin. Both passes clear before anything goes to print, and before anything goes to the laboratory. The sequencing logic is in freeze the label, then test, then file.

Mistake four: prohibited or restricted ingredients, usually from consulting the wrong list

Bottom line: most ingredient problems trace to using another jurisdiction's positive list. Permitted substances, conditions of use and limits in the Philippines are whatever current FDA rules say, and they do not necessarily overlap with the framework you know.

What it looks like. Four variants:

• The formulation contains something prohibited in the Philippines. Years of lawful sale in the country of origin does not mean every constituent is permitted here.
• The substance is permitted, but not for this use. Permitted use of many additives is tied to food categories — the same additive can be allowed in one category and not in the one you are declaring.
• Use levels exceed what is allowed. Limits follow current FDA rules; do not extrapolate from home-country standards or third-party compilations.
• The declaration is not granular enough to judge. Compound raw materials given only by trade name, or an additive declared merely as flavouring with no functional class or standard name, leaves the evaluator unable to determine whether it falls within permitted use, so a letter goes out. Strictly this is a declaration error rather than an ingredient error, but the consequence is identical.

Why it happens. Because ingredient review is the one step that has to be done before anything else is committed, and most companies reach it only during document collection — by which point the formulation is fixed, packaging has been proofed, and sometimes the goods are already produced. Discovering a problem at that point changes the cost entirely.

What it costs, in two tiers. Insufficient granularity is cured with a supplementary explanation. An ingredient that is genuinely not acceptable, or not acceptable in this category, means reformulating or dropping the SKU — and reformulating means retesting, redoing artwork and rebuilding the dossier.

How to catch it before filing. Tabulate the full formulation, with compound raw materials broken down to actual constituents and processing aids included, and check every line against current FDA rules for that food category — and do it before the formulation is locked, not after packaging is proofed. Where a substance is uncertain, ask before you produce. Halal markets carry a separate framework of their own; see halal certification in the Philippines.

Mistake five: testing done wrong — scope, header, or an unaccepted laboratory

Bottom line: testing is the one step where money can be spent and produce nothing usable, and all three ways of wasting a report are avoidable before samples are sent.

One: incomplete scope. Parameters must cover the groups the category requires, which depending on product characteristics can span physicochemical, microbiological, contaminant and additive areas, with the actual list taken from current FDA requirements. The common error is running a standard export panel, or a home-market panel, which then does not align with what is expected here. Retesting is not only more money; it is another scheduling cycle, during which the file sits suspended.

Two: the report header does not match the filing. Product name, specification, net content, batch and production date on the report must match the dossier exactly. The usual cause is testing before the label or the specification was finalised — nothing is wrong with the report itself, it simply no longer describes the product you are registering. This failure is purely a sequencing problem; see freezing the label before testing.

Three: the issuing laboratory is not accepted. Recognition differs between local and overseas laboratories, and acceptability should be confirmed before samples go out rather than after results come back. This is pure information cost, and it is skipped constantly.

There is also a timing variant: reports that are too old. Even where no expiry is printed, reviewers generally have expectations about currency. Filing a new registration on a report from several years ago, or continuing to rely on the original report after a long deficiency round, can trigger a request to retest.

How to catch it before filing. Confirm three things before sending samples: that the laboratory is acceptable, that the parameter groups cover the category requirement, and that the sample description matches the frozen label and master data exactly. Then check the header word for word when the report arrives. Laboratory charges follow the current quotation of whichever laboratory takes the work and vary considerably with the parameter set. Document-level validity issues are covered in the document set and its expiry table.

The remaining recurring errors, and a twelve-point pre-filing check

Bottom line: beyond the main five there is a cluster of recurring errors, all sharing one root — treating registration as a one-off event.

• Bundling different variants or formulations into one application. Registration is granted per product. Different flavours, different formulations and different pack sizes generally file separately. Bundling to save a filing fee usually returns the whole application.
• Treating the CPR as a universal permit. A product registration settles whether the product may lawfully be sold in the Philippines. It does not handle entry, quarantine or local business permits. Products with animal or plant origin components have a separate agricultural track — see permits required to import food — and border release is covered in import commodity clearance.
• Shipping first and registering afterwards. The most directly costly of all. Without the registration the goods cannot lawfully be placed on the market even if they clear entry, and the holding costs are entirely yours.
• Filing and forgetting. Certificates have validity periods, and changes to formulation or labeling may require a variation or a new filing. That is covered in renewal before the certificate expires.
• Believing guaranteed approvals and fixed day counts. Nobody can commit to an outcome, and nobody can commit to a duration — one deficiency round removes the file from active review and requeues it. Fees follow the current FDA and laboratory schedules.

Twelve-point pre-filing check:

1. The applicant is a licensed local entity and certificate ownership is agreed.
2. The licensed activities cover this filing.
3. Neither the licence nor the local business permit expires inside the projected review period.
4. Company name and address read identically on the licence, the corporate registration and the authorisation.
5. The letter of authorisation covers product registration and is in force.
6. Master data is fixed: product name, specification, net content, pack, batch convention, shelf life.
7. The label has been audited item by item and frozen.
8. Label, formulation declaration, specification sheet and test report agree three ways.
9. The formulation is broken down to actual constituents and checked against current rules.
10. The laboratory is confirmed acceptable and the parameter groups cover the category.
11. The report header matches master data exactly and the report is current enough.
12. All foreign documents are legalised and none expire inside the review window.

Whatever fails this list is what your next deficiency letter will cite. What to do when one arrives is covered in handling a rejection.